Skip to main content

HPV-Management Forum

Novosanis is looking forward to joining the HPV-Management forum, a congress about the Papilloma Virus Associated Neoplasia that focuses on Diagnostics, Therapy and Prevention. The congress, organized by the AG of the Paul Ehrlich Society for Chemotherapy e.V., will take place in Heidelberg, Germany, on 29 February 2020.

Henk Joos, our business development manager for Europe, is excited to meet you there and give you more information about our unique urine capturing device that has shown great potential in Human Papillomavirus (HPV) detection. Visit our booth to learn more.

Disclaimer

Novosanis is a wholly owned subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology. The Colli-Pee® family, the heart of the company, allows volumetric and standardized collection of first-void urine. The platform consists of variants capturing a range of urine volumes for different application purposes. Urine collection through the Colli-Pee® device is easy, comfortable, and more accurate than a regular urine cup. First-void urine has shown to improve detection of infectious diseases, including sexually transmitted infections as well as for some cancers applications. The Colli-Pee® device enables immediate mixing of the first-void urine sample with a preservative, improving stability of the urine specimen. Novosanis markets its products worldwide and has a global customer base.